Orca Bio Strengthens Leadership Team with Key Appointments Ahead of Potential Commercial Launch
Orca Bio has appointed Steve Gavel as Chief Commercial Officer and Allison Frisbee as Senior Vice President, Legal, marking a strategic move to bolster its leadership team as it prepares for the potential commercial launch of its lead investigational therapy, Orca-T®.
Orca Bio, a late-stage biotechnology company, has announced the appointment of Steve Gavel as Chief Commercial Officer and Allison Frisbee as Senior Vice President, Legal. These strategic hires come as the company advances its lead investigational allogeneic T-cell immunotherapy, Orca-T®, toward a potential commercial launch. Gavel, with over 30 years of experience in the biotechnology and pharmaceutical sectors, including a significant role in the commercialization of cell and gene therapies, is expected to lead Orca Bio into its next phase of growth. Frisbee brings extensive experience in legal and regulatory challenges within the life science industry, aiming to strengthen the company's legal and compliance functions.
The appointments underscore Orca Bio's commitment to transforming the therapeutic landscape for patients with high-risk blood cancers, such as acute myeloid leukemia and myelodysplastic syndrome. With approximately 500 patients treated in trials to date, the company's high-precision cell therapy platform shows promising potential. The addition of seasoned executives like Gavel and Frisbee is a critical step in preparing for the commercial launch of Orca-T®, ensuring the company is well-positioned to navigate the complexities of bringing innovative therapies to market. This move not only highlights Orca Bio's growth trajectory but also its dedication to improving patient outcomes through advanced cell therapies.